IP Library Granted Patent US 10,314,881
Granted Patent B2
US 10,314,881 · App. 16/019,589 · Granted Jun 11, 2019

SMAC mimetic

Inventors: Stephen M. Condon (Glenmoore, PA); Yijun Deng (Dresher, PA); Matthew G. Laporte (Honeybrook, PA); Susan R. Rippin (Wilmington, DE)
Assignee: Medivir AB
A61K38/05A61K31/404A61K31/555A61K38/07A61K45/06A61N5/062A61N5/10C07D403/06C07D403/14C07K5/02C07K5/06C07K5/06026C12N5/0693A61K38/00C12N2500/46Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,881
App. No.
16/019,589
Granted
Jun 11, 2019
Kind
B2
Abstract

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Claims (10)

1. A method for the treatment of breast cancer, prostate cancer, rectal cancer, head and neck cancers, gynecological tumors, bladder cancer and lymphoma in a mammal in need thereof that comprises administering an effective amount of Compound 15 of the following formula:

wherein R5 is —CH2CH3, or a pharmaceutically acceptable salt thereof, in combination with a second cancer therapy that is radiotherapy.

2. The method of claim 1 , wherein the radiotherapy is applied just to the localized area involved with a tumor.

3. The method of claim 2 , wherein the radiotherapy further comprises applying the radiotherapy to draining lymph nodes.

4. The method of claim 1 , wherein the radiotherapy is teletherapy.

5. The method of claim 1 , wherein the radiotherapy is sealed source radiotherapy.

6. The method of claim 2 wherein the tumor is a head and neck cancer.

7. The method of claim 6 , wherein the radiotherapy further comprises applying the radiotherapy to draining lymph nodes.

8. The method of claim 6 , wherein the radiotherapy is teletherapy.

9. The method of claim 6 , wherein the radiotherapy is sealed source radiotherapy.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 047436 FRAME: 0203. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 25, 2021
From: TETRALOGIC BIRINAPANT UK LTD.
To: MEDIVIR AB
Reel/Frame 056392/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: TETRALOGIC BIRINAPANT UK
To: MEDIVIR AB
Reel/Frame 047436/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2018
From: CONDON, STEPHEN M.; DENG, YIJUN; LAPORTE, MATTHEW G.; RIPPIN, SUSAN R.
To: TETRALOGIC PHARMACEUTICALS CORP.
Reel/Frame 046211/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2018
From: TETRALOGIC PHARMACEUTICALS CORPORATION
To: TETRALOGIC BIRINAPANT UK LTD
Reel/Frame 046211/0957 →
Continuity (7)
Continuation 15344813 · Nov 7, 2016
Continuation 14607752 · Jan 28, 2015
Continuation 14075190 · Nov 8, 2013
Continuation 13611274 · Sep 12, 2012
Division 12819221 · Jun 20, 2010
Provisional Application 61222668 · Jul 2, 2009
Related Publication 20180303897A1 · Oct 25, 2018